pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)
Merck Sharp and Dohme
MSD Merck Sharp drug portfolio — 130 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 130 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MSD Merck Sharp drug portfolio — 130 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L02) compound in MSD Merck Sharp's portfolio. Molecular target: Androgen receptor.
US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
US regulatory status: approved.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Mechanism: Phosphodiesterase 3 inhibitor.
US regulatory status: approved. Molecular target: Phosphodiesterase 3.
Various (V09) compound in MSD Merck Sharp's portfolio. Mechanism: Diagnostic agent.
US regulatory status: approved. Molecular target: Substance-P receptor.
US regulatory status: approved. Molecular target: Cyclooxygenase.
US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
US regulatory status: approved. Molecular target: Endothelial PAS domain-containing protein 1.
US regulatory status: approved. Molecular target: ATP-citrate synthase.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
Antiinfectives for systemic use (J05) compound in MSD Merck Sharp's portfolio. Molecular target: Human immunodeficiency virus type 1 integrase.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
US regulatory status: approved.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Mechanism: Unknown.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Programmed cell death protein 1.
US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
US regulatory status: approved. Molecular target: Histamine H2 receptor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
US regulatory status: approved.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Envelope glycoprotein E.
US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Glucagon receptor.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Nectin-4.
US regulatory status: approved. Molecular target: Androgen receptor.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: DNA topoisomerase II.
US regulatory status: approved. Molecular target: Aromatase.
US regulatory status: approved. Molecular target: NPC1-like intracellular cholesterol transporter 1.
US regulatory status: approved. Molecular target: Histamine H2 receptor.
Various (V09) compound in MSD Merck Sharp's portfolio. Mechanism: Diagnostic agent.
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Follicle-stimulating hormone receptor.
Genito-urinary system and sex hormones (G03) compound in MSD Merck Sharp's portfolio. Molecular target: Follicle-stimulating hormone receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
US regulatory status: approved. Molecular target: Tubulin.
Antiinfectives for systemic use (J07) compound in MSD Merck Sharp's portfolio. Molecular target: Envelope glycoprotein E.
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
Antiinfectives for systemic use (J07) compound in MSD Merck Sharp's portfolio. Mechanism: Biological vaccine - induces immune response.
Antiinfectives for systemic use (J07) compound in MSD Merck Sharp's portfolio. Mechanism: Biological vaccine - induces immune response.
Antiinfectives for systemic use (J07) compound in MSD Merck Sharp's portfolio. Mechanism: Biological vaccine - induces immune response.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Ribonucleoside-diphosphate reductase RR1.
US regulatory status: approved. Molecular target: Ribonucleoside-diphosphate reductase RR1.
US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
US regulatory status: approved. Molecular target: Aromatase.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Progesterone receptor.
US regulatory status: approved. Molecular target: Progesterone receptor.
Antiinfectives for systemic use (J05) compound in MSD Merck Sharp's portfolio. Molecular target: RNA.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Poly [ADP-ribose] polymerase 2.
US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Epidermal growth factor receptor.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved. Molecular target: CDK6/cyclin D1.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: B-cell antigen receptor complex-associated protein beta chain.
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
US regulatory status: approved. Mechanism: Supplement.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Progesterone receptor.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor 2.
US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
Development asset linked to MSD Merck Sharp in public FDA and regional records.
US regulatory status: approved.
Cardiovascular system (C02) compound in MSD Merck Sharp's portfolio. Molecular target: Inhibin beta A chain.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
Antiinfectives for systemic use (J05) compound in MSD Merck Sharp's portfolio.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Hepatocyte growth factor receptor.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Tissue factor.
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: DNA topoisomerase 1.
US regulatory status: approved. Molecular target: Retinoic acid receptor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved.
US regulatory status: approved. Molecular target: Soluble guanylate cyclase.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Mechanism: Tubulin inhibitor.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Mechanism: Tubulin inhibitor.
Antineoplastic and immunomodulating agents (L01) compound in MSD Merck Sharp's portfolio. Molecular target: Tubulin.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Mechanism: Tubulin inhibitor.
Development asset linked to MSD Merck Sharp in public FDA and regional records. Molecular target: Inactive tyrosine-protein kinase transmembrane receptor ROR1.